The report will be delivered in 2-3 business days.

Biosimilar Lymphocyte Modulator Global Market Report 2021 - By Drug (Campath-1H, Natalizumab Biosimilar, Efalizumab - A1089-Anti-CD11a Bisoimilar, Anti-CD38 Daratumumab Biosimilar, Anti-CS1 Elotuzumab Bisoimilar), By Disease (Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Psoriasis), COVID-19 Growth And Change

Starting Price : $5000.00 | Pages : 175 | Published : March 2021 | SKU CODE : 7754 | Format :


The biosimilar lymphocyte modulator market consists of sales of immune regulating lymphocyte modulators by entities (organizations, sole traders and partnerships) that manufacture lymphocyte modulator biosimilars. Lymphocyte modulators are intended as an aid in the treatment for cancer and autoimmune diseases, and for regulating carotene intake in humans with a weak immune system. Only goods and services traded between entities or sold to end consumers are included.

The biosimilar lymphocyte modulator market covered in the report is segmented by drug into campath-1H, natalizumab biosimilar, efalizumab - A1089-anti-CD11A biosimilar, anti-CD38 daratumumab biosimilar, anti-CS1 elotuzumab biosimilar and by disease into arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, psoriasis, others.

The global biosimilar lymphocyte modulator market is expected to grow from $1.22 billion in 2020 to $1.31 billion in 2021 at a compound annual growth rate (CAGR) of 7.4%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The biosimilar lymphocyte modulator market is expected to reach $1.91 billion in 2025 at a CAGR of 10%.

Immunotherapy combined with other cancer treatments is expected to drive the growth of the biosimilar lymphocyte modulators market. The combination of immunotherapies or pairing of immunotherapies with other types of cancer treatments such as chemotherapy or radiation enhances the benefit associated with lymphocyte modulators. According to a study conducted by the researchers at Washington University School of Medicine in St. Louis, combining two immunotherapy strategies into one can give better results for certain blood cancers such as leukaemia. Evidence suggests that this new approach could be safer with reduced side effects than other cellular immunotherapies such as CAR-T cell. The combination approach, therefore, saves patients’ life from a life-threatening reaction of the immune system thereby driving the growth of the lymphocyte modulator market.

The shortage of raw material for lymphocyte modulator drugs is expected to restrict the growth of the biosimilar lymphocyte modulator market. Drug shortages are due to several factors including challenges for acquiring raw materials, manufacturing problems, regulatory issues, business decisions, and numerous disturbances within the supply chain. They adversely affect patient care by causing the replacement of safe and effective therapies with elective medicines, compromising or delaying medical procedures, or causing medication errors. For instance, in January 2019, the American Society of Haematology, an association comprising of clinical scientists and physicians that provides care to patients in diverse settings, sent a letter to USFDA highlighting the issue of shortage of critical hematologic drugs such as etoposide and methotrexate, which have no alternatives. Mainly the drug etoposide, which is a chemotherapeutic drug, that is a crucial component in treatment regimens designed to be curative for life-threatening conditions including leukaemia and lymphomas. Due to the shortage, some patients have received less effective treatment. Thus, the raw material shortages cause delayed and compromised medical treatments and also results in limiting the growth of the market.

Tumor-Infiltrating Lymphocyte Immunotherapy has been gaining popularity in recent times because of its positive results in anti-cancer treatments. Tumor-infiltrating lymphocytes (TILs) comprise of all lymphocytic cell populaces that have occupied the tumor tissue. TILs have been depicted in various solid tumors including breast cancer, and are emerging as a significant biomarker in predicting the efficacy and result of treatment. Due to promising results, many companies have started launching TIL technologies. For instance, in January 2020, Lovance Biotherapeutics, a US-based start-up company, has licensed TALEN technology from Cellectis to develop gene-editing tumor-infiltrating lymphocytes (TIL) to treat several cancer indications. Other companies investing in TIL technology are Optera Therapeutics Corp and TILT Biotherapeutics.

In July 2020, Cytocom, Inc., a US-based immunotherapy generating company, announced the acquisition with ImQuest Life Sciences, Inc. for an undisclosed sum. The deal is expected to support Cytocom’s vision of strategic growth and strengthen internal drug development programs with new assets and secured revenue-generating operations, scientific resources, and tools and capacity. ImQuest Life Sciences is a US-based company with leading drug discovery and development. The company was founded in 2004.

Major players in the biosimilar lymphocyte modulator market are Pfizer, Biogen, Genentech, Novartis, and Celltrion.

The regions covered in the biosimilar lymphocyte modulator market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the biosimilar lymphocyte modulator market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The global biosimilar lymphocyte modulator market is segmented -

1) By Drug: Campath-1H, Natalizumab Biosimilar, Efalizumab - A1089-Anti-CD11a Bisoimilar, Anti-CD38 Daratumumab Biosimilar, Anti-CS1 Elotuzumab Bisoimilar

2) By Disease: Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Psoriasis, Others

    Table Of Contents

    1. Executive Summary

    2. Biosimilar Lymphocyte Modulator Market Characteristics

    3. Biosimilar Lymphocyte Modulator Market Trends And Strategies

    4. Impact Of COVID-19 On Biosimilar Lymphocyte Modulator

    5. Biosimilar Lymphocyte Modulator Market Size And Growth

    5.1. Global Biosimilar Lymphocyte Modulator Historic Market, 2015-2020, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Biosimilar Lymphocyte Modulator Forecast Market, 2020-2025F, 2030F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Biosimilar Lymphocyte Modulator Market Segmentation

    6.1. Global Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    Campath-1H

    Natalizumab Biosimilar

    Efalizumab - A1089-Anti-CD11a Bisoimilar

    Anti-CD38 daratumumab Biosimilar

    Anti-CS1 elotuzumab Bisoimilar

    6.2. Global Biosimilar Lymphocyte Modulator Market, Segmentation By Disease, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    Arthritis

    Diabetes

    Multiple Myeloma

    Enterocolitis

    Multiple Sclerosis

    Psoriasis

    Others

    7. Biosimilar Lymphocyte Modulator Market Regional And Country Analysis

    7.1. Global Biosimilar Lymphocyte Modulator Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    7.2. Global Biosimilar Lymphocyte Modulator Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    8. Asia-Pacific Biosimilar Lymphocyte Modulator Market

    8.1. Asia-Pacific Biosimilar Lymphocyte Modulator Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    9. China Biosimilar Lymphocyte Modulator Market

    9.1. China Biosimilar Lymphocyte Modulator Market Overview

    9.2. China Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

    10. India Biosimilar Lymphocyte Modulator Market

    10.1. India Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    11. Japan Biosimilar Lymphocyte Modulator Market

    11.1. Japan Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    12. Australia Biosimilar Lymphocyte Modulator Market

    12.1. Australia Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    13. Indonesia Biosimilar Lymphocyte Modulator Market

    13.1. Indonesia Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    14. South Korea Biosimilar Lymphocyte Modulator Market

    14.1. South Korea Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    15. Western Europe Biosimilar Lymphocyte Modulator Market

    15.1. Western Europe Biosimilar Lymphocyte Modulator Market Overview

    15.2. Western Europe Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    16. UK Biosimilar Lymphocyte Modulator Market

    16.1. UK Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    17. Germany Biosimilar Lymphocyte Modulator Market

    17.1. Germany Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    18. France Biosimilar Lymphocyte Modulator Market

    18.3. France Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    19. Eastern Europe Biosimilar Lymphocyte Modulator Market

    19.1. Eastern Europe Biosimilar Lymphocyte Modulator Market Overview

    19.2. Eastern Europe Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    20. Russia Biosimilar Lymphocyte Modulator Market

    20.1. Russia Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    21. North America Biosimilar Lymphocyte Modulator Market

    21.1. North America Biosimilar Lymphocyte Modulator Market Overview

    21.2. North America Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    22. USA Biosimilar Lymphocyte Modulator Market

    22.1. USA Biosimilar Lymphocyte Modulator Market Overview

    22.2. USA Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    23. South America Biosimilar Lymphocyte Modulator Market

    23.1. South America Biosimilar Lymphocyte Modulator Market Overview

    23.2. South America Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    24. Brazil Biosimilar Lymphocyte Modulator Market

    24.1. Brazil Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    25. Middle East Biosimilar Lymphocyte Modulator Market

    25.1. Middle East Biosimilar Lymphocyte Modulator Market Overview

    25.2. Middle East Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    26. Africa Biosimilar Lymphocyte Modulator Market

    26.1. Africa Biosimilar Lymphocyte Modulator Market Overview

    26.2. Africa Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    27. Biosimilar Lymphocyte Modulator Market Competitive Landscape And Company Profiles

    27.1. Biosimilar Lymphocyte Modulator Market Competitive Landscape

    27.2. Biosimilar Lymphocyte Modulator Market Company Profiles

    27.2.1. Pfizer

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Biogen

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Genentech

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Novartis

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Celltrion

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Biosimilar Lymphocyte Modulator Pipeline Analysis

    29. Key Mergers And Acquisitions In The Biosimilar Lymphocyte Modulator Market

    30. Biosimilar Lymphocyte Modulator Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Research Inquiries

    31.4. The Business Research Company

    31.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2015-2020, $ Billion
  • Table 2: Global Forecast Market Growth, 2020-2025F, 2030F, $ Billion
  • Table 3: Global Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 4: Global Biosimilar Lymphocyte Modulator Market, Segmentation By Disease, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 5: Global Biosimilar Lymphocyte Modulator Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 6: Global Biosimilar Lymphocyte Modulator Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 7: Asia-Pacific, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 8: China, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 9: India, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 10: Japan, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 11: Australia, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 12: Indonesia, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 13: South Korea, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 14: Western Europe, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 15: UK, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 16: Germany, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 17: France, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 18: Eastern Europe, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 19: Russia, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 20: North America, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 21: USA, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 22: South America, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 23: Brazil, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 24: Middle East, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 25: Africa, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 26: Pfizer Financial Performance
  • Table 27: Biogen Financial Performance
  • Table 28: Genentech Financial Performance
  • Table 29: Novartis Financial Performance
  • Table 30: Celltrion Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2015-2020, $ Billion
  • Figure 2: Global Forecast Market Growth, 2020-2025F, 2030F, $ Billion
  • Figure 3: Global Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 4: Global Biosimilar Lymphocyte Modulator Market, Segmentation By Disease, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 5: Global Biosimilar Lymphocyte Modulator Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 6: Global Biosimilar Lymphocyte Modulator Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 7: Asia-Pacific, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 8: China, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 9: India, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 10: Japan, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 11: Australia, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 12: Indonesia, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 13: South Korea, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 14: Western Europe, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 15: UK, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 16: Germany, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 17: France, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 18: Eastern Europe, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 19: Russia, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 20: North America, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 21: USA, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 22: South America, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 23: Brazil, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 24: Middle East, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 25: Africa, Biosimilar Lymphocyte Modulator Market, Segmentation By Drug, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 26: Pfizer Financial Performance
  • Figure 27: Biogen Financial Performance
  • Figure 28: Genentech Financial Performance
  • Figure 29: Novartis Financial Performance
  • Figure 30: Celltrion Financial Performance
Global Psoriasis Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Psoriatic Arthritis Treatment Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Regenerative Medicine For Cartilage Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Radiopharmaceuticals Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Remdesivir Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Research Antibodies and Reagents Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Rituximab Biosimilars Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Respiratory Diseases Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Biosimilar Monoclonal Antibodies Global Market Report 2021 - By Type (Synthetic Chemicals, Biopharmaceuticals), By Application (Chronic & Autoimmune Diseases, Oncology), By Compound (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab), COVID-19 Growth And Change
View Report
Biosimilar Therapeutic Peptides Global Market Report 2021 - By Route Of Administration (Parenteral Route, Transdermal Route), By Application (Cancer, Cardiovascular, Central Nervous Systems, Metabolic Disorders, Infection, Hematological Disorders, Gastrointestinal Disorders, Dermatology, Respiratory Disorders), By Type (Innovative, Generic), COVID-19 Growth And Change
View Report
Rituximab Biosimilars Global Market Report 2021 - By Application (Non-Hodgkin's Lymphoma, Chronic Lymhocytic Leukemia, Rheumatoid Arthritis), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Direct Distribution Channels), By Route Of Administration (Subcutaneous, Intravenous, Molecular Type), COVID-19 Growth And Change
View Report
Biosimilar Hormones Global Market Report 2021 - By Type (Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars), By Application (Research & Biotechnology, Diagnostics, Biocatalysts, Therapeutics), By Distribution Channel (Hospital And Retail Pharmacy, Online Pharmacy/epharmacy, Speciality Clinics), COVID-19 Growth And Change
View Report
Biosimilar Lymphocyte Modulator Global Market Report 2021 - By Drug (Campath-1H, Natalizumab Biosimilar, Efalizumab - A1089-Anti-CD11a Bisoimilar, Anti-CD38 Daratumumab Biosimilar, Anti-CS1 Elotuzumab Bisoimilar), By Disease (Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Psoriasis), COVID-19 Growth And Change
View Report
Biosimilars Global Market Report 2021 - By Product (Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins), By Types (Human Growth Hormone, Erythropoietin, Monoclonal Antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor), By Application (Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases), COVID-19 Growth And Change
View Report
Filgrastim Biosimilars Market - By Application (Oncology, Chronic and Autoimmune Diseases, Blood disorders, Growth hormone deficiency, Others), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies), And By Region, Opportunities And Strategies – Global Filgrastim Biosimilars Market Forecast To 2030
View Report
Pegfilgrastim Biosimilars Market - By Application (Chemotherapy Induced Neutropenia, Transplantation, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail Order/Online Pharmacies), And By Region, Opportunities And Strategies – Global Pegfilgrastim Biosimilars Market Forecast To 2030
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)